| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Like its unlabeled counterpart, this compound targets anaerobic bacteria and protozoa. As a deuterated metabolite standard, it is primarily used for monitoring drug residues and does not possess an independent pharmacological target。
|
|---|---|
| ln Vitro |
This compound is not used for in vitro pharmacological activity assessment; its in vitro application is exclusively analytical. It is spiked into biological samples (e.g., tissues, eggs, milk) as an internal standard for sample preparation prior to instrumental analysis。
|
| ln Vivo |
Hydroxy ipronidazole-d3 is not administered to animals for pharmacological effect studies. Instead, it is used in residue analysis: the deuterated compound is spiked into blank animal-derived samples to construct calibration curves for quantifying ipronidazole residues in livestock products.
|
| Enzyme Assay |
Non-cell assays involve LC-MS/MS method development. The compound (typically 1-100 ng/mL) is dissolved in mobile phase and infused directly into the LC-MS/MS system to optimize MRM transitions. Isotope dilution calibration curves are prepared by spiking fixed concentrations of the deuterated standard into solutions containing varying levels of the unlabeled analyte.
|
| Cell Assay |
Cell-based assays are not applicable as this compound is not a biological active pharmaceutical. In analytical contexts, the compound is sometimes added to fortified tissue homogenates (e.g., liver, muscle) which contain cellular debris, to assess extraction recovery and matrix effects during LC-MS/MS method validation.
|
| Animal Protocol |
Animal experiments with this compound are not performed. For unlabeled ipronidazole, in vivo efficacy studies are conducted in swine for swine dysentery and histomoniasis. The deuterated version is used only as an analytical standard for measuring parent drug and metabolite levels in samples from such studies.
|
| ADME/Pharmacokinetics |
As a stable isotope-labeled compound, its ADME properties are identical to unlabeled Hydroxy ipronidazole: it is formed from ipronidazole via hydroxylation, has a half-life of approximately 6-12 hours in livestock, and is primarily excreted in urine and feces. It is used as an internal standard in PK studies.
|
| Toxicity/Toxicokinetics |
The unlabeled Hydroxy ipronidazole has potential mutagenic activity similar to its parent nitroimidazole compound. Hepatotoxicity and reproductive toxicity have been observed with nitroimidazole drugs. The deuterated form is considered safe for laboratory handling at analytical quantities.
|
| References | |
| Additional Infomation |
This compound is exclusively a research reagent and internal standard for LC-MS/MS residue monitoring in food safety testing. It is not approved for human or animal therapeutic use and should be stored at -20degC as a neat solid or in solution.
|
| Molecular Formula |
C7H8D3N3O3
|
|---|---|
| Molecular Weight |
188.20
|
| Exact Mass |
188.099
|
| CAS # |
1156508-86-9
|
| Related CAS # |
Hydroxy ipronidazole;35175-14-5
|
| PubChem CID |
71749080
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
108-110°C
|
| LogP |
1.078
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
214
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N1C(=CN=C1C(C)(C)O)[N+](=O)[O-]
|
| InChi Key |
DTHPMNDYKOSVFR-HPRDVNIFSA-N
|
| InChi Code |
InChI=1S/C7H11N3O3/c1-7(2,11)6-8-4-5(9(6)3)10(12)13/h4,11H,1-3H3/i3D3
|
| Chemical Name |
2-[5-nitro-1-(trideuteriomethyl)imidazol-2-yl]propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3135 mL | 26.5675 mL | 53.1350 mL | |
| 5 mM | 1.0627 mL | 5.3135 mL | 10.6270 mL | |
| 10 mM | 0.5313 mL | 2.6567 mL | 5.3135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
